Topic:Software Technologies used in Clinical trials.
Abstract: Extreme poverty is negatively impacting clinical trial subjects in 3rd world countries in many ways. Using disruptive technology concepts, not only empowers these subjects to access important platforms and patient support programs, but also increases the overall safety of the trial. The ability to reverse charge any costs associated with accessing ePRO platforms (or similar) will enable study coordinators to keep a close eye on the patient population between visits.
Biography:Adriaan Kruger have 20 years’ experience in Enterprise Application Development and implementation including 7+ years’ experience in Clinical Data Management and Drug Development digitization. He led and managed many global and regional multinational projects and teams in various capacities. He was recruited out of varsity to join a small Oracle Consulting start-up in 2008 which was later acquired by EOH Holdings Limited (listed on Johannesburg Stock Exchange). Within EOH I ended up working as a Divisional Head across various verticals, including Oracle Enterprise Application and Engineered Solutions. Today He lead a group of exceptionally gifted team members at nuvoteQ.io (a software company I co-founded in 2014) where we are empowering our customers to digitize their industries (mainly life sciences) in a simplified, yet innovative manner. He is passionate about start-ups and disruptive technologies shaping the world and fascinated by the gifted individuals who make it happen.
Topic:How to set up a successful Clinical Trial?.
Abstract: Project teams have employed creative solutions for decade to ensure successful Clinical Trials.The standard outcome is delayed start-up activities and missing to achieve sponsor milestones.Let’s explore the different ways in which sponsor or CRO companies may choose to collaborate to deliver a successful Clinical Trial.
Biography:Mike Failly is the founder and Managing Director of Zanteris, a Clinical Operations & Outsourcing company, who provides tailored Clinical Operations solutions for Pharma, CRO and Biotech to maximize the execution of clinical trials.Zanteris provide Clinical Operations expertise to conduct phase I to IV research in various therapeutic areas such as Oncology, Immuno-Oncology, Immunology, and Cardiology and a customized approach in Clinical Project Manager development using Leadership skill set as a pillar.Mike brings the experience and lessons learned of 50+ projects and programs over 13 years of industry experience with a consistent ‘can do’ attitude. His mission is to provide a different approach in delivering Clinical Operations & Outsourcing services, but also to work differently from that of the mass market.Mike holds a Ph.D in Neurobiology. He is a former Associate Project Director, his experience background includes roles as Study Coordinator, Clinical Trial Associate, Clinical Team Manager and Project Management roles within CRO, pharma industry company and hospital for more than a decade before founding what is now Zanteris.Over the last 5 years, Mike’s focus was on supporting Associate Project Managers/Project Managers development, through line management and development of Project Manager mindset, but also to support corporate initiative and dedicate his Project Management skills to manage complex studies or program.
Topic:Emerging Technologies and Trends within Clinical Trials.
Abstract: Triall is building towards the world’s first multi-sided platform for all clinical research professionals. Applying an enterprise-grade blockchain infrastructure, Triall will host a series of modular eClinical solutions that directly tailor to identified pain points that make clinical operations overly complex, lengthy, and resource-inefficient. Triall’s first deliverable: a blockchain-integrated eTMF.
Biography:Hadil Es-Sbai, MSc., Co-founderand CEO at Triall
Hadil majored in analytical chemistry at the VU University Amsterdam,the Netherlands. He has a background of 20+ years in clinical development and assumed several roles within the pharmaceutical and clinical contract research industries. He became an entrepreneur in 2006 and has since combined several functions that are all related to business development and innovation in the pharmaceutical and clinical domain.
